Savolitinib and osimertinib combination significantly improves PFS in EGFR-mutated NSCLC with MET amplification compared to ...

Patients prescribed the combination therapy should be given anticoagulant prophylaxis to prevent VTE during the first 4 months of treatment. The Food and Drug Administration (FDA) has approved ...

Sunvozertinib shows promise for NSCLC with EGFR exon 20 insertion mutations, achieving a 53.3% ORR in the WU-KONG1 trial. The FDA application is supported by phase 2 trial data, with a focus on ORR ...

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) ...

In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%. The Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy ® (sunvozertinib) for ...

The European Commission has approved Tagrisso (osimertinib; AstraZeneca) combined with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced epidermal ...

Brain metastases are a common problem in patients with EGFR-mutated non-small cell lung cancer (NSCLC), occurring in about one-fifth to one-quarter of patients. Many brain metastases will be ...

NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of ...

Dr. Jacob Sands discusses the significance of the FDA approval of Datroway for the treatment of patients with locally advanced or metastatic EGFR+ NSCLC. On June 23, 2025, the U.S. Food and Drug ...

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...